Deutsche Bank Ag\ Bellus Health Inc. Transaction History

Deutsche Bank Ag\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$8.22 - $10.76 $44,519 - $58,276	5,416 New	5,416 $44,000
Q2 2022 Aug 11, 2022	BUY	$6.46 - $10.02 $34,987 - $54,268	5,416 New	5,416 $50,000
Q3 2021 Nov 04, 2021	SELL	$2.7 - $6.64 $264,011 - $649,272	-97,782 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$3.11 - $4.61 $279,533 - $414,356	89,882 Added 1137.75%	97,782 $304,000
Q1 2021 May 13, 2021	SELL	$3.03 - $4.58 $113,191 - $171,095	-37,357 Reduced 82.54%	7,900 $30,000
Q4 2020 Feb 16, 2021	SELL	$2.27 - $3.3 $78,428 - $114,015	-34,550 Reduced 43.29%	45,257 $138,000
Q3 2020 Nov 12, 2020	SELL	$2.14 - $12.02 $13,083 - $73,490	-6,114 Reduced 7.12%	79,807 $181,000
Q2 2020 Aug 13, 2020	BUY	$8.88 - $11.15 $762,978 - $958,019	85,921 New	85,921 $884,000
Q1 2020 May 14, 2020	SELL	$5.77 - $10.85 $49,789 - $93,624	-8,629 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.76 - $7.6 $49,127 - $64,820	8,529 Added 8529.0%	8,629 $65,000
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $624 - $884	100 New	100 $0

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.